Lantheus Holdings Inc
NASDAQ:LNTH
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
4.3B USD |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
60B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
8.9T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
29.6B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
109.6B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.6B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
42.8B CNY |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD |
Loading...
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
3.9B CHF |
Loading...
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
4.8B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Lantheus Holdings Inc is 62.2%, which is below its 3-year median of 63.8%.
Over the last 3 years, Lantheus Holdings Inc’s Gross Margin has increased from 58.9% to 62.2%. During this period, it reached a low of 58.9% on Sep 30, 2022 and a high of 64.8% on Sep 30, 2024.